Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $54.7300 (1.62%) ($54.7300 - $54.7300) on Mon. Dec. 21, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.25% (three month average) | RSI | 88 | Latest Price | $54.7300(1.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 4.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 38.3% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(61%) ARKK(58%) IWO(58%) IBB(57%) | Factors Impacting TGTX price | TGTX will decline at least -3.125% in a week (0% probabilities). VIXM(-40%) VXX(-36%) UUP(-19%) UNG(-3%) EDOC(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.125% (StdDev 6.25%) | Hourly BBV | 2.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $52.96(3.34%) | 10 Day Moving Average | $45.78(19.55%) | 20 Day Moving Average | $37.62(45.48%) | To recent high | 0% | To recent low | 130.7% | Market Cap | $6.932b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |